Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules

Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage disease that is extensively disseminated intraperitoneally and prognosticates the poorest outcomes. Primarily metastatic within the abdominal cavity, ovarian carcinomas initially spread to adjacent organs by direct extension and then disseminate via the transcoelomic route to distant sites. Natural fluidic streams of malignant ascites triggered by physiological factors, including gravity and negative subdiaphragmatic pressure, carry metastatic cells throughout the peritoneum. We investigated the role of fluidic forces as modulators of metastatic cancer biology in a customizable microfluidic platform using 3D ovarian cancer nodules. Changes in the morphological, genetic, and protein profiles of biomarkers associated with aggressive disease were evaluated in the 3D cultures grown under controlled and continuous laminar flow. A modulation of biomarker expression and tumor morphology consistent with increased epithelial–mesenchymal transition, a critical step in metastatic progression and an indicator of aggressive disease, is observed because of hydrodynamic forces. The increase in epithelial–mesenchymal transition is driven in part by a posttranslational up-regulation of epidermal growth factor receptor (EGFR) expression and activation, which is associated with the worst prognosis in ovarian cancer. A flow-induced, transcriptionally regulated decrease in E-cadherin protein expression and a simultaneous increase in vimentin is observed, indicating increased metastatic potential. These findings demonstrate that fluidic streams induce a motile and aggressive tumor phenotype. The microfluidic platform developed here potentially provides a flow-informed framework complementary to conventional mechanism-based therapeutic strategies, with broad applicability to other lethal malignancies.

[1]  Savas Tasoglu,et al.  Manipulating biological agents and cells in micro-scale volumes for applications in medicine. , 2013, Chemical Society reviews.

[2]  R. Iozzo,et al.  The Dermatan Sulfate Proteoglycan Decorin Modulates α2β1 Integrin and the Vimentin Intermediate Filament System during Collagen Synthesis , 2012, PloS one.

[3]  K. Shen,et al.  The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. , 2012, Cancer epidemiology.

[4]  P. Leung,et al.  EGF-Induced EMT and Invasiveness in Serous Borderline Ovarian Tumor Cells: A Possible Step in the Transition to Low-Grade Serous Carcinoma Cells? , 2012, PloS one.

[5]  P. Donahoe,et al.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance , 2012, Proceedings of the National Academy of Sciences.

[6]  K. Sawada,et al.  Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer , 2011, Journal of oncology.

[7]  Paulo A. S. Nuin,et al.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer , 2012, BMC Cancer.

[8]  Chih-Ming Ho,et al.  Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma , 2012, Journal of Biomedical Science.

[9]  Hyungil Jung,et al.  Integration of intra- and extravasation in one cell-based microfluidic chip for the study of cancer metastasis. , 2011, Lab on a chip.

[10]  V. Budach,et al.  Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[12]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[13]  S. Agarwal,et al.  Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. , 2011, The American journal of pathology.

[14]  Umut A. Gurkan,et al.  Enumeration of CD4+ T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients , 2011, PloS one.

[15]  Denis Wirtz,et al.  The physics of cancer: the role of physical interactions and mechanical forces in metastasis , 2011, Nature Reviews Cancer.

[16]  William J. Polacheck,et al.  Interstitial flow influences direction of tumor cell migration through competing mechanisms , 2011, Proceedings of the National Academy of Sciences.

[17]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  E. Dejana,et al.  Adhesion molecule signalling: not always a sticky business , 2011, Nature Reviews Molecular Cell Biology.

[20]  Yosef Yarden,et al.  Feedback regulation of EGFR signalling: decision making by early and delayed loops , 2011, Nature Reviews Molecular Cell Biology.

[21]  T. Hasan,et al.  A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. , 2011, Biotechnology journal.

[22]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[23]  Tayyaba Hasan,et al.  Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. , 2010, Cancer research.

[24]  Tayyaba Hasan,et al.  Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. , 2010, Cancer research.

[25]  Marian Brennan,et al.  Integrins as therapeutic targets: lessons and opportunities , 2010, Nature Reviews Drug Discovery.

[26]  Tayyaba Hasan,et al.  Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. , 2010, Journal of biomedical optics.

[27]  E. Lengyel Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[28]  E. Dickerson,et al.  Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[29]  Tayyaba Hasan,et al.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. , 2010, Chemical reviews.

[30]  M. Quinn,et al.  Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. , 2010, Current cancer drug targets.

[31]  Hideo Baba,et al.  Epithelial–mesenchymal transition in cancer development and its clinical significance , 2010, Cancer science.

[32]  Laurie G. Hudson,et al.  Targeting the EGF Receptor for Ovarian Cancer Therapy , 2009, Journal of oncology.

[33]  Adnan O. Abu-Yousif,et al.  PuraMatrix Encapsulation of Cancer Cells , 2009, Journal of visualized experiments : JoVE.

[34]  F. Portillo,et al.  The morphological and molecular features of the epithelial-to-mesenchymal transition , 2009, Nature Protocols.

[35]  K. Krause,et al.  Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. , 2009, Critical reviews in oncology/hematology.

[36]  P. Holm-Nielsen PATHOGENESIS OF ASCITES IN PERITONEAL CARCINOMATOSIS1 , 2009 .

[37]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[38]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[39]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[40]  E. Lengyel,et al.  MMP-2 functions as an early response protein in ovarian cancer metastasis , 2009, Cell cycle.

[41]  Andrew J. Lindsay,et al.  Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.

[42]  N. Lange,et al.  Combination of photodynamic therapy with anti-cancer agents. , 2008, Current medicinal chemistry.

[43]  Karen D. Cowden Dahl,et al.  Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. , 2008, Cancer research.

[44]  Ludger Hengst,et al.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy , 2008, Nature Reviews Cancer.

[45]  E. Kistner,et al.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. , 2008, Cancer research.

[46]  S. Chien,et al.  Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad , 2008, Proceedings of the National Academy of Sciences.

[47]  M. Quinn,et al.  Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm , 2007, Journal of cellular physiology.

[48]  E. Lengyel,et al.  Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum , 2007, International journal of cancer.

[49]  M. Manimaran,et al.  Multi-step microfluidic device for studying cancer metastasis. , 2007, Lab on a chip.

[50]  Melody A Swartz,et al.  Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. , 2007, Cancer cell.

[51]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[52]  S. Steinberg,et al.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.

[53]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[54]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[55]  S. Hahn,et al.  Intraperitoneal photodynamic therapy. , 2007, Cancer treatment and research.

[56]  E. Vokes,et al.  A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[58]  R. Agarwal,et al.  Mechanisms of transcoelomic metastasis in ovarian cancer. , 2006, The Lancet. Oncology.

[59]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[60]  S. Dedhar,et al.  Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. , 2006, American journal of physiology. Cell physiology.

[61]  A. Skubitz,et al.  Disaggregation and invasion of ovarian carcinoma ascites spheroids , 2006, Journal of Translational Medicine.

[62]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[63]  B. Pogue,et al.  Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. , 2005, Journal of the National Cancer Institute.

[64]  E. Brown,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.

[65]  M. Esteller,et al.  Loss of E‐cadherin mediated cell–cell adhesion as an early trigger of apoptosis induced by photodynamic treatment , 2005, Journal of cellular physiology.

[66]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[67]  N. Sonenberg,et al.  Translational control in stress and apoptosis , 2005, Nature Reviews Molecular Cell Biology.

[68]  James M. Roberts,et al.  Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors? , 2004, Nature Reviews Cancer.

[69]  C. Elie,et al.  Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) , 2004, British Journal of Cancer.

[70]  Y. Adam,et al.  Malignant ascites: past, present, and future. , 2004, Journal of the American College of Surgeons.

[71]  E. Holland,et al.  Postgenomic global analysis of translational control induced by oncogenic signaling , 2004, Oncogene.

[72]  A. Skubitz,et al.  Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. , 2004, Gynecologic oncology.

[73]  P. Sugarbaker,et al.  Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread , 2003, Cancer and Metastasis Reviews.

[74]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[76]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[77]  Mina J Bissell,et al.  Modeling tissue-specific signaling and organ function in three dimensions , 2003, Journal of Cell Science.

[78]  Jayanta Debnath,et al.  The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.

[79]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[80]  Rork Kuick,et al.  Integrating cancer genomics and proteomics in the post‐genome era , 2002, Proteomics.

[81]  N. Hacker,et al.  Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. , 2001, Journal of the National Cancer Institute.

[82]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[83]  Roger E Bumgarner,et al.  Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. , 2001, Science.

[84]  Timothy Zhu,et al.  Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors , 2001, Annals of Surgical Oncology.

[85]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[86]  J. Foidart,et al.  Vimentin contributes to human mammary epithelial cell migration. , 1999, Journal of cell science.

[87]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[88]  T. Hasan,et al.  BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and β1 integrin expression in ovarian cancer cells , 1999, British Journal of Cancer.

[89]  V. Weaver,et al.  Tissue structure, nuclear organization, and gene expression in normal and malignant breast. , 1999, Cancer research.

[90]  C. Arteaga,et al.  Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. , 1998, Experimental cell research.

[91]  T. Hasan,et al.  Integrin-mediated adhesion and signalling in ovarian cancer cells. , 1998, Cellular signalling.

[92]  S S Cross,et al.  FRACTALS IN PATHOLOGY , 1997, The Journal of pathology.

[93]  P. Sugarbaker Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. , 1996, Cancer treatment and research.

[94]  O. C. Sandall,et al.  Diffusion coefficients for hydrogen sulfide, carbon dioxide, and nitrous oxide in water over the temperature range 293--368 K , 1994 .

[95]  M. Bissell,et al.  Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[96]  C. Herman,et al.  Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[97]  M. Winker,et al.  Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. , 1986, Biochemical pharmacology.

[98]  R. Knapp,et al.  The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. , 1972, Cancer research.

[99]  P. Holm-Nielsen Pathogenesis of ascites in peritoneal carcinomatosis. , 1953, Acta pathologica et microbiologica Scandinavica.